Literature DB >> 32658253

Error in the Biomarker Subsection.

.   

Abstract

Year:  2020        PMID： 32658253      PMCID： PMC7358976          DOI： 10.1001/jamaneurol.2020.2416

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  1 in total

1.  Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.

Authors:  Alette M Wessels; Pierre N Tariot; Jennifer A Zimmer; Katherine J Selzler; Sonja M Bragg; Scott W Andersen; John Landry; James H Krull; AnnCatherine M Downing; Brian A Willis; Sergey Shcherbinin; Jamie Mullen; Peter Barker; Jennifer Schumi; Craig Shering; Brandy R Matthews; Robert A Stern; Bruno Vellas; Sharon Cohen; Emer MacSweeney; Mercè Boada; John R Sims
Journal:  JAMA Neurol       Date:  2020-02-01       Impact factor: 18.302
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.